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Neil P. Shah, Charles Chuah, Luis Casanova, Brigid Bradley-Garelik, George Manos, and Andreas Hochhaus
A B S T R A C T
Purpose
We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naı̈ve
Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety
outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with
dasatinib or imatinib.
Patients and Methods
Patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib 100 mg once
daily (n = 259) or imatinib 400 mg once daily (n = 260).
Results
At the time of study closure, 61% and 63% of dasatinib- and imatinib-treated patients remained on
initial therapy, respectively. Cumulative rates of major molecular response and molecular responses
with a 4.0- or 4.5-log reduction in BCR-ABL1 transcripts from baseline by 5 years remained statistically
significantly higher for dasatinib comparedwith imatinib. Rates for progression-free and overall survival
at 5 years remained high and similar across treatment arms. In patients who achieved BCR-ABL1
# 10% at 3 months (dasatinib, 84%; imatinib, 64%), improvements in progression-free and overall
survival and lower rates of transformation to accelerated/blast phase were reported compared with
patients with BCR-ABL1 greater than 10% at 3 months. Transformation to accelerated/blast phase
occurred in 5% and 7% of patients in the dasatinib and imatinib arms, respectively. Fifteen dasatinib-
treated and 19 imatinib-treated patients had BCR-ABL1mutations identified at discontinuation. There
were no new or unexpected adverse events identified in either treatment arm, and pleural effusion
was the only drug-related, nonhematologic adverse event reported more frequently with dasatinib
(28% v 0.8%with imatinib). First occurrences of pleural effusionwere reportedwith dasatinib,with the
highest incidence in year 1. Arterial ischemic events were uncommon in both treatment arms.
Conclusion
These final results from the DASISION trial continue to support dasatinib 100mg once daily as a safe
and effective first-line therapy for the long-term treatment of CML-CP.
J Clin Oncol 34:2333-2340. © 2016 by American Society of Clinical Oncology
INTRODUCTION
TheDasatinib Versus Imatinib Study in Treatment-
Na ı̈ve Chronic Myeloid Leukemia Patients
(DASISION) study was a randomized phase III
trial comparing the efficacy and safety of dasatinib
with imatinib in patients with newly diagnosed
chronic myeloid leukemia (CML) in chronic phase
(CP). Initial results showed that dasatinib had met
its primary end point of superior efficacy com-
pared with imatinib and had an acceptable safety
profile, leading to its approval for first-line use.1,2
In subsequent analyses,3-6 dasatinib contin-
ued to demonstrate deep and fast responses.
Progression-free survival (PFS) and overall sur-
vival (OS) remained high and comparable be-
tween dasatinib and imatinib. Furthermore, the
safety profile of dasatinib was consistent through
each update.
Several studies with BCR-ABL1 tyrosine ki-
nase inhibitors (TKIs) have reported that a deep,
early response predicts improved outcomes in
patients with CML-CP.5,7-18 The achievement of
BCR-ABL1 transcript levels of # 10% according
to the International Scale (IS) at 3 months has
© 2016 by American Society of Clinical Oncology 2333
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been associated with significantly improved PFS, event-free sur-
vival, and OS and a reduced risk of transformation.5,8,9,14
Here, we present the final, planned, 5-year analysis from
DASISION. Long-term efficacy and safety outcomes, CML-related
and -unrelated deaths, and BCR-ABL1 mutation status are re-
ported. Expected survival by age at diagnosis and response by Euro
(Hasford) risk score are described.
PATIENTS AND METHODS
Study Design and Treatment
DASISION was a multinational, open-label, phase III trial (CA180-
056; ClinicalTrials.gov identifier: NCT00481247). Patients were stratified
by Euro risk score19 and randomly assigned 1:1 to receive either oral
dasatinib (100 mg once daily) or imatinib (400 mg once daily). Adverse
events (AEs) were managed through treatment interruptions and dose
reductions. Dose escalations to dasatinib 140mg once daily or imatinib 600
to 800 mg once daily were permitted for suboptimal response at 3 to
18 months.20 The primary end point was confirmed complete cytogenetic
response (cCCyR) rate by 12 months. Secondary end points were overall
time to cCCyR and its duration, major molecular response (MMR) rate at
any time, time to MMR overall, PFS, and OS.
Patients
Eligibility criteria and patient characteristics have been described,1
and key exclusion criteria are available in the Appendix (online only).
Patients with uncontrolled or serious cardiovascular disease were not
eligible, but those with common cardiovascular risk factors (uncontrolled
hypertension or angina, congestive heart failure . 3 months before en-
rollment, and myocardial infarction . 6 months before enrollment) were
eligible. The trial was approved by all institutional review boards and ethics
committees. All patients gave written informed consent before random
assignment in accordance with the Declaration of Helsinki.
Evaluations
Analyses after a minimum follow-up of 5 years are presented
(database lock: March 24, 2014). Complete cytogenetic response (CCyR)
was defined as 0% Philadelphia chromosome–positive cells in $ 20 bone
marrow metaphases. MMR and molecular responses MR4 and MR4.5
represent BCR-ABL1 transcript levels of# 0.1%,# 0.01%, and# 0.0032%
(IS), corresponding to a 3-log, 4-log, and 4.5-log reduction from a stan-
dardized baseline, respectively.10,20,21 Missing samples and patients with
atypical BCR-ABL1 transcripts (not b2a2 or b3a2) were considered
nonresponders. A central laboratory (MolecularMD, Portland, OR) per-
formed molecular assessments. Treatment failure was defined as no he-
matologic response at 3 months, no complete hematologic response or no
cytogenetic response at 6 months, no partial cytogenetic response at
12 months, no CCyR at 18 months, or progression at any time.20 Protocol-
defined disease progression, on the basis of guidelines available during
protocol design,20 included doubling of WBC count to greater than 20 3
109/L, loss of complete hematologic response, increase in Philadelphia
chromosome–positive bone marrow metaphases to $ 30% from nadir,
transformation to accelerated/blast phase (AP/BP), or death from any
cause. Transformation to CML-AP/BP did not include clonal evolution.20
Patients who agreed to follow-up (. 98% in each arm) continued to be
observed for transformation and survival for up to 5 years. Expected
patient life spans by treatment were calculated by applying the OS rate as
a percentage of the life span of the general population without CML.22
Poststudy CML treatment was to be captured for all patients. AEs were
graded according to National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0.23 Mutations were assessed at
discontinuation of study treatment in patients with sufficient BCR-ABL1
cDNA for amplification using Sanger direct sequencing (MolecularMD).
Statistical Considerations
Cumulative response rates were calculated using the cumulative
incidence approach and Kaplan-Meier method. Comparisons of MR rates
were performed using Cochran-Mantel-Haenszel testing methodology and
stratified by Euro score. Unstratified comparison of rates by Euro score was
performed using an exact test. Post hoc analyses compared response rates
at various time points; therefore, P values are descriptive and unadjusted
for multiple comparisons. PFS and OS were estimated using Kaplan-Meier
analysis. For PFS, patients who discontinued the study without progression
were censored at the date of their last on-study hematologic or cytogenetic
evaluation. Progression and transformation data after study discontinu-
ation were obtained for patients who agreed to follow-up. For OS, patients
were censored on the date they were last known to be alive. Hazard ratios
(HRs) were based on the Cox model.
RESULTS
Patient Disposition
Of 519 patients enrolled onto DASISION, 259 were randomly
assigned to receive dasatinib, and 260 were randomly assigned to
receive imatinib (Fig 1), with well-balanced baseline characteristics
in each arm.1 After 5 years, 61% of dasatinib-treated patients and
63% of imatinib-treated patients were still on initial therapy
(Table 1 and Appendix Table A1, online only). The median average
daily dose for treated patients was 99 mg (range, 21 to 139 mg) for
dasatinib and 400 mg (range, 125 to 741 mg) for imatinib. Patients
who discontinued the study as a result of study closure received
99 mg (range, 56 to 139mg) of dasatinib and 400mg (range, 287 to
741 mg) of imatinib, and patients who discontinued the study as
a result of all other reasons received 95 mg (range, 21 to 127 mg) of
dasatinib and 400 mg (range, 125 to 740 mg) of imatinib. After
discontinuation, the most common subsequent treatments were
imatinib (19%), nilotinib (9%), dasatinib (3%), and hydroxyurea
(2%) for the dasatinib arm, and dasatinib (16%), imatinib (11%),
nilotinib (9%), and hydroxyurea (3%) for the imatinib arm. All
other poststudy CML treatments were reported for less than 2% of
patients. Some patients continued the treatment received in
DASISION after discontinuation from study drug.
Efficacy
Cumulative, 5-year MMR and MR4.5 rates were 76% and 42%
for dasatinib and 64% and 33% for imatinib, respectively (P =
.0022 and P = .0251, respectively; Fig 2). Proportions of randomly
assigned patients with responses at 5 years in the dasatinib and
imatinib arms were 28% and 26% for cCCyR, 52% and 49% for
MMR, 39% and 28% for MR4, and 25% and 18% for MR4.5,
respectively. At study end, patients were not required to provide
samples for bone marrow cytogenetics, possibly leading to lower
values for cCCyR in both arms. The achievement of MMR and
MR4.5 at any time by Euro score was also investigated (Appendix
Fig A1, online only). Significant differences between dasatinib- and
imatinib-treated patients were observed for MMR in the low-risk
group (P , .001) and for MR4.5 in the intermediate-risk group
(P = .0218).
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Estimated 5-year OSwas 91% for dasatinib and 90% for imatinib
(HR, 1.01; 95%CI, 0.58 to 1.73; Appendix Fig A2, online only). In the
analysis of expected life span by age at diagnosis, the age-adjusted life
expectancy for patients with CML-CP in both arms of DASISION
approached that for patients from an external, non-CMLpopulation22
(Appendix Fig A3, online only). More imatinib-treated patients died
as a result of CML-related causes (n = 17) compared with dasatinib-
treated patients (n = 9); however, the related 5-year OS was not statis-
tically significantly different (P = .1192; HR, 0.53; 95% CI, 0.24 to 1.19).
Estimated 5-year PFS was 85% for dasatinib and 86% for
imatinib (HR, 1.06; 95% CI, 0.68 to 1.66; Appendix Fig A2).
Including follow-up beyond on-study treatment discontinuation
(intent to treat), 4.6% and 7.3% of patients on dasatinib and
imatinib, respectively, transformed to AP/BP by 5 years. Two
patients in the imatinib group and none in the dasatinib group
transformed between 3 and 5 years.
As reported previously, a higher percentage of dasatinib-
treated patients achieved BCR-ABL1 # 10% (IS) at 3 months
compared with imatinib-treated patients (84% and 64%, re-
spectively).5 The proportions of dasatinib-treated patients age 65
and younger and older than 65 years who achieved BCR-ABL1 #
10% (IS) at 3 months were similar, as were the proportions of
Table 1. Patient Status at 5 Years
Status
No. of Patients (%)
Dasatinib 100 mg Once Daily
(n = 258)
Imatinib 400 mg Once Daily
(n = 258)
On initial therapy at study end 158 (61) 162 (63)
Discontinued
Progression or treatment failure 28 (11) 36 (14)
Intolerance* 42 (16) 17 (7)
AE unrelated to study treatment 12 (5) 4 (2)
Poor compliance/nonadherence 1 (, 1) 7 (3)
Patient request 4 (2) 10 (4)
Withdrawal of consent 4 (2) 3 (1)
Lost to follow-up 1 (, 1) 2 (1)
Other 8 (3)† 16 (6)‡
Abbreviation: AE, adverse event.
*As decided by investigator. Intolerance is defined as recurrent grade $ 3 hematologic toxicity or grade $ 2 nonhematologic toxicity requiring discontinuation despite
dose reduction.
†Includes insufficient molecular response (n = 3), pregnancy (n = 2), loss of complete cytogenetic response (n = 1), increased BCR-ABL1 (n = 1), and relocation to the
United States (n = 1).
‡Includes nomolecular response/loss of molecular response (n = 4), suboptimal response (n = 3), insufficient cytogenetic response (n = 2), investigator request (n = 2),
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Fig 1. CONSORT diagram for the
DASISION trial after a minimum follow-up
of 5 years. CML-CP, chronic myeloid
leukemia in chronic phase; Ph+, Phila-
delphia chromosome positive. (*) Rea-
sons for discontinuation are listed in
Table 1.
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imatinib-treated patients age 65 and younger and older than 65
years. In both arms, patients who achieved BCR-ABL1# 10% (IS)
at 3months more often reached CCyR,MMR, andMR4.5 by 5 years
(Table 2), had higher rates of OS and PFS (Fig 3), and had a lower
transformation rate (3% v 14% to 15% in patients who did not
achieve BCR-ABL1 # 10% at 3 months).
Mutational Analysis
Testing for BCR-ABL1mutations was planned in all patients at
treatment or study discontinuation (Appendix Table A2, online
only). Of the available samples, 200 patients (81%) in the dasatinib
arm and 214 patients (83%) in the imatinib arm had mutation
analysis performed. Mutations were identified in 15 (8%) of 200
patients and 19 (9%) of 214 patients in the dasatinib and imatinib
arms, respectively. T315I mutations were identified in eight
dasatinib-treated patients and no imatinib-treated patients. Most
patients who had mutations discontinued treatment as a result of
progression or treatment failure (dasatinib, n = 13 of 15 patients;
imatinib, n = 14 of 19 patients).
Safety
No new AEs were observed with dasatinib or imatinib by
5 years. Overall, most AEs reported with both drugs were grade 1 or
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Fig 2. Cumulative response rates over time. The
percentages of patients with (A) major molecular
response (MMR) and (B) molecular response with
a 4.5-log reduction in BCR-ABL1 transcripts from
baseline (MR4.5; BCR-ABL1 transcript level #
0.0032% [International Scale]) by 1, 2, 3, 4, and 5
years are shown.
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with imatinib were grade 3 or 4. Rates of grade 3 or 4 hematologic
AEs were higher for dasatinib versus imatinib (neutropenia, 29% v
24%; anemia, 13% v 9%; and thrombocytopenia, 22% v 14%,
respectively). Except for pleural effusion, drug-related, non-
hematologic AEs were reported less frequently with dasatinib than
imatinib or were comparable (Fig 4). Drug-related AEs were
Table 2. Five-Year Responses by BCR-ABL1 (IS) Transcript Levels at 3 Months
Response
% of Patients
Dasatinib 100 mg Once Daily
(n = 259)




(n = 198; 84%)
3-Month BCR-ABL1 Transcript
Level . 10%
(n = 37; 16%)
3-Month BCR-ABL1 Transcript
Level # 10%
(n = 154; 64%)
3-Month BCR-ABL1 Transcript
Level . 10%
(n = 85; 36%)
Complete cytogenetic
response
94 41 92 59
Major molecular
response
87 38 81 41
MR4.5 54 5 48 12
Abbreviations: IS, International Scale; MR4.5, molecular response with a 4.5-log reduction in BCR-ABL1 transcripts from baseline (BCR-ABL1 transcript level# 0.0032% [IS]).
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Fig 3. Estimated 5-year (A, B) overall survival (OS) and (C, D) progression-free survival (PFS) by molecular response at 3 months for both treatment arms. OS and PFS
were calculated using patients on study treatment and in follow-up after discontinuation of randomly assigned treatment.
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manageable, leading to discontinuation in 16% and 7% of patients
in the dasatinib and imatinib arms, respectively.
Drug-related pleural effusion was more common with
dasatinib (28%) than with imatinib (0.8%). Sixty-six patients
(26%) experienced grade 1 or 2, seven patients (3%) experi-
enced grade 3 or 4, and no patients experienced grade 5 pleural
effusion on dasatinib. Pleural effusion developed in approxi-
mately 8% of at-risk dasatinib-treated patients in year 1 of
therapy and was comparable each subsequent year (Appendix
Table A3, online only). The percentage of patients who de-
veloped pleural effusions was higher in patients age $ 65 years
(15 of 25 patients; 60%) compared with patients younger than
age 65 years (58 of 233 patients; 25%). Drug-related pleural
effusion was managed with dose interruption (62%) and/or
dose reduction (41%), diuretics (47%), corticosteroids (32%),
or therapeutic thoracocentesis (12%). Only 15 patients (6%)
discontinued dasatinib and only one patient discontinued
imatinib as a result of pleural effusion. Pleural effusion did not
impair the ability of patients to obtain a response; 71 patients
(96%) achieved a cCCyR, 61 (82%) achieved an MMR, and 37
(50%) achieved an MR4.5.
Pulmonary hypertension (PH), which was diagnosed with
two-dimensional echocardiography, was reported in 14 dasatinib-
treated patients (5%) and one imatinib-treated patient (0.4%). Of
the 14 PH diagnoses in dasatinib-treated patients, nine patients had
pleural effusion. Right heart catheterization is recommended by
the WHO to confirm moderate to severe precapillary PH and
establish a diagnosis of pulmonary arterial hypertension (PAH).24
However, only one dasatinib-treated patient with PH had this
procedure performed, and it did not support a diagnosis of PAH.
The remaining 13 patients with a PH diagnosis were not evaluated
according to these criteria. Of the 14 PH diagnoses, 12 were drug
related.
Because arterial ischemic events have been described during
TKI therapy for CML,25 cardiovascular, cerebrovascular, and pe-
ripheral vascular events were evaluated. Arterial ischemic events
were uncommon in both the dasatinib (5%) and imatinib (2%)
treatment arms (Appendix Table A4, online only). Seven of 10
cardiovascular ischemic events occurred within year 1 of dasatinib
therapy; most patients restarted dasatinib without a recurrent
event. Additionally, two dasatinib-treated patients (imatinib, n = 0)
had a transient ischemic attack, and two imatinib-treated patients
(dasatinib, n = 0) had peripheral arterial disease. No patients
experienced a stroke.
Twenty-six patients (10%) died in each arm by 5 years,
a fraction within 30 days of their last treatment (eight patients
[3%] in the dasatinib arm and five patients [2%] in the imatinib
arm). Four deaths, three in dasatinib-treated patients and one in
imatinib-treated patients, were reported after the start of sub-
sequent CML therapy (n = 3 on nilotinib; n = 1 on nilotinib and
imatinib after dasatinib discontinuation). Overall, causes of death
included cardiovascular disease (dasatinib, n = 2; imatinib, n = 1);
disease progression (dasatinib, n = 9; imatinib, n = 17); infection
(dasatinib, n = 11; imatinib, n = 1); other malignancy, septic
shock and cardiac failure, multiorgan failure, and whole-body
swelling (dasatinib, n = 1 each); stem-cell transplantation
complications and unknown cause (imatinib, n = 2 each); and
severe chest pain, clinical deterioration and decrease in perfor-
mance status, and fatal bleeding (imatinib, n = 1 each). Four of 11
dasatinib-treated patients who died of infection died within
30 days of their last dose (Klebsiella meningoencephalitis, sepsis,
pneumonia, and unknown cause). The remaining seven patients
died of various forms of infection (encephalitis, aspiration
pneumonia, pulmonary infection, jaundice/malarial fever, sepsis,
septic shock, and unknown cause) between 69 days and 4.5 years
after their last dose, with two patients having transformed to AP/
BP before death. Only one patient who died as a result of infection
had neutropenia, and this patient discontinued dasatinib more
than 4 years before death.
DISCUSSION
The final study results from DASISION confirm that dasatinib-
treated patients have high MR rates and that the achievement of
BCR-ABL1 # 10% (IS) at 3 months is predictive of significantly
higher PFS and OS rates. The dasatinib arm had more patients
achieve BCR-ABL1# 10% (IS) at 3months and fewer CML-related
deaths (nine of 26 patients v 17 of 26 patients in dasatinib and
imatinib arms, respectively). The benefit of dasatinib has been














Favors dasatinib Favors imatinib
Odds Ratio (Dasatinib v Imatinib) With 95% CI
Fig 4. Drug-related, nonhematologic ad-
verse events (AEs) reported in $ 10% of
patients. Odds ratios (dasatinib v imatinib)
with 95% CIs are shown for AEs that oc-
curred in $ 10% of patients. Blue favors
dasatinib, and gold favors imatinib.
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confirmed in additional randomized trials,26-28 making the data
supporting the overall benefit with dasatinib robust.
PFS and OS rates remain high and comparable between the
two treatment arms, with more dasatinib patients achieving early
treatment milestones. Patients with CML are now living almost
as long as the general population.29 Therefore, given high OS
rates (approximately 90% at 5 years) and a majority of patients
achieving CCyR, a larger population over a longer period of time
may demonstrate a statistically significant survival difference.
Another possible explanation for indistinguishable survival
benefit is that 26% of patients were treated with the second-
generation TKIs dasatinib (16%) or nilotinib (9%) after dis-
continuation of imatinib, which can rescue patients with imatinib
failure.
Notably, in an intent-to-treat analysis, a disproportionate
number of dasatinib-treated patients (n = 11) died as a result of
infection compared with imatinib-treated patients (n = 1). Most
infection deaths (n = 7 of 11 deaths) occurred between 69 days and
4.5 years after dasatinib was discontinued, including five patients
who were receiving nilotinib or imatinib at the time of infection.
Prior studies with dasatinib as initial therapy for CML have not
reported a significant increase in risk of infections.27,28,30,31
However, follow-up for these studies at the time of this report
was either short or included only preliminary results. It will be
important to prospectively and intentionally look at a possible
imbalance in the occurrence of infections and, if present, de-
termine a possible mechanism(s) for dasatinib-related infectious
complications.
Few patients in either arm developed BCR-ABL1mutations.
Different numbers of patients with mutations were identified
here and in the 3-year mutational analysis of DASISION.
Mutations assessed in the 3-year report were from a more di-
verse patient population, those with an on-treatment event (no
cCCyR and no MMR within 12 months, five-fold increase in
BCR-ABL1 with loss of MMR, or loss of CCyR).32 Here, T315I
mutations were identified with dasatinib (n = 8) but not
imatinib. Previous reports have demonstrated a 2% rate of
T315I mutations after a median of 31 months on imatinib,33
making the absence of this mutation in DASISION unexpected.
One possible explanation for the disparity in T315I mutations
between the two study arms is the decreased diversity in mu-
tations that are resistant to dasatinib versus those that are re-
sistant to imatinib, resulting in fewer mutants to dominate
resistance mechanisms. It has been suggested that some mu-
tations (ie, Y253H/F, E255K) may confer higher transformation
potency in vitro than others (ie, T315I).32 If true, one could
speculate that the more proliferative clones would emerge.
However, if these were suppressed by dasatinib, less pro-
liferative, unsuppressed clones would predominate. Further
studies are required to investigate this hypothesis. Most patients
with mutations discontinued treatment because of progression
or treatment failure, consistent with the 3-year analysis.32
The safety profile for dasatinib remains consistent, with no
new safety signals identified after 5 years. Other than pleural ef-
fusion, the most common drug-related nonhematologic AEs were
either similar between dasatinib and imatinib or lower with
dasatinib. Pleural effusion was more common with dasatinib,
occurred throughout this trial, and led to discontinuation in 6% of
patients. Almost all patients (96%) with pleural effusion achieved
cCCyR, and 82% achieved MMR. These results suggest that, with
adequate management, patients with pleural effusion may be able
to remain on dasatinib. Serious, but rare, AEs have been reported
with use of TKIs in CML, including hepatotoxicity34 and renal
dysfunction with imatinib,35 PAH with dasatinib,24,36 cardiac and
vascular events with nilotinib,37 and arterial and venous throm-
bosis and occlusions with ponatinib.38 Some dasatinib-treated
patients experienced PH. There were no reports of PAH fitting
the criteria defined by WHO, which require right heart cathe-
terization, although this procedure was only attempted in one
patient, making the evaluation of true PAH incidence in this report
inaccurate. As previously reported,39 there may be an association
between PH and pleural effusion because nine of 14 patients with
PH also had pleural effusion. Awareness and investigation of PH
are important aspects of proper management of dasatinib-treated
patients.
Arterial ischemic events were not common in either treatment
arm. No dasatinib-treated patients experienced peripheral arterial
disease. Rates of cardiovascular ischemic events on dasatinib (4%)
and imatinib (2%) were similar to those reported in the general
population.40,41 Nonetheless, physicians should be aware of these
cardiovascular ischemic events, effectively manage comorbidities,
and identify these events promptly.
AEs have been reported to increase nonadherence to TKIs.42,43
The proportion of patients in DASISION who discontinued
dasatinib or imatinib as a result of poor compliance or non-
compliance was small. It is currently unclear whether patients
treated in community practices would have similarly low levels of
noncompliance to TKIs outside of a clinical trial. Given that
noncompliance has been shown to negatively affect treatment
responses and outcomes,43-46 it is an important question to address
in future studies to support successful treatment of CML.
In summary, the final, long-term results from DASISION
demonstrated that patients taking dasatinib had faster and deeper
MRs than patients taking imatinib. However, at the time of this
final report, PFS and OS rates were similar for both cohorts. There
were no new safety signals observed with dasatinib through 5 years
or with longer follow-up. These results suggest that first-line
dasatinib should continue to be considered a standard first-line
therapy for patients with newly diagnosed CML-CP.
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Key exclusion criteria were as follows: serious, uncontrolled medical disorders or active infections; a corrected QT interval of
more than 450 milliseconds; history of a serious bleeding disorder unrelated to chronic myeloid leukemia; previous or concurrent
malignancy (excluding adequately treated basal or squamous cell skin cancer, cervical carcinoma in situ, or stage I or II cancer in
remission, or patients with previous cancer who have been disease free for$ 3 years); previous chemotherapy for peripheral stem-
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Fig A1. (A) Major molecular response (MMR) and (B) molecular response with
a 4.5-log reduction in BCR-ABL1 transcripts from baseline (MR4.5; BCR-ABL1
transcript level # 0.0032% [International Scale]) at any time by Euro (Hasford)
risk score.

















Dasatinib 259 253 248 245 241 236 233 230 227 222 219 219 218 218 218 213 211 207 206 203 186 105 61 31 3 0
Imatinib 260 255 251 245 239 233 228 225 221 220 217 216 214 210 208 207 199 195 194 190 174 100 59 29 3 0
Months



























Dasatinib 259 254 253 249 247 245 245 242 242 239 236 234 234 231 228 227 226 223 222 220 212 117 67 37 3 0
Imatinib 260 257 255 253 251 247 246 244 241 240 238 235 231 229 227 225 221 217 216 211 196 113 67 35 4 0
Months
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Fig A2. Kaplan-Meier curves for (A) overall survival and (B) progression-free survival in both treatment arms. A sensitivity analysis of progression-free survival was
performed to include patients who discontinued treatment and experienced progression or died on treatment or during follow-up.
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General population*
45
< 40 40-49 50-59





























Fig A3. Expected survival by age at diagnosis for both treatment arms and
a general population of patientswithout chronicmyeloid leukemia. (*) Expected life
span estimates were adapted from Ludwig et al.22
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Table A1. AEs Leading to Treatment Discontinuation Regardless of Relationship to Study Treatment
AE
No. of Patients (%)
Dasatinib 100 mg Once Daily (n = 258) Imatinib 400 mg Once Daily (n = 258)
Patients* with any AE† leading to discontinuation 50 (19) 26 (10)
Pleural effusion 15 (6) 1 (, 1)
Pulmonary hypertension 6 (2) 0
Blast phase in myelogenous leukemia 3 (1) 3 (1)
Thrombocytopenia 3 (1) 2 (1)
Dyspnea 2 (1) 0
Leukopenia 2 (1) 0
Acute myocardial infarction 2 (1) 0
Pericardial effusion 2 (1) 0
Chest pain 2 (1) 0
Diarrhea 1 (, 1) 1 (, 1)
Acute renal failure 1 (, 1) 1 (, 1)
Pleuritis 1 (, 1) 0
Pneumothorax 1 (, 1) 0
Pulmonary embolism 1 (, 1) 0
Lung adenocarcinoma 1 (, 1) 0
Transitional-cell carcinoma 1 (, 1) 0
Peripheral edema 1 (, 1) 0
Abdominal discomfort 1 (, 1) 0
Abdominal pain 1 (, 1) 0
Colitis 1 (, 1) 0
Pancreatic disorder 1 (, 1) 0
Bronchopneumonia 1 (, 1) 0
Infection 1 (, 1) 0
Meningoencephalitis, bacterial 1 (, 1) 0
Creatine phosphokinase increased 1 (, 1) 0
ECG QT prolonged 1 (, 1) 0
Diabetes mellitus 1 (, 1) 0
Renal failure 1 (, 1) 0
Optic neuritis 1 (, 1) 0
Blast cell proliferation 0 2 (1)
Neutropenia 0 2 (1)
Rash 0 2 (1)
Colon cancer 0 1 (, 1)
Nodal marginal zone B-cell lymphoma 0 1 (, 1)
Rectal carcinoma 0 1 (, 1)
Myocardial infarction 0 1 (, 1)
Asthenia 0 1 (, 1)
Performance status decreased 0 1 (, 1)
Alopecia 0 1 (, 1)
Erythema 0 1 (, 1)
Palmar-plantar erythrodysesthesia 0 1 (, 1)
Maculopapular rash 0 1 (, 1)
ALT increased 0 1 (, 1)
AST increased 0 1 (, 1)
Hypocalcemia 0 1 (, 1)
Hypophosphatemia 0 1 (, 1)
Cytogenetic abnormality 0 1 (, 1)
Toxic hepatitis 0 1 (, 1)
Abbreviation: AE, adverse event.
*Patients may have had more than one AE.
†AEs listed were reported by investigators at the time of treatment discontinuation and were defined as any new untoward medical occurrence or worsening of a pre-
existing medical condition in a patient. AEs did not necessarily have a causal relationship with study treatment.
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Table A2. BCR-ABL1 Mutations at the Time of Discontinuation
Mutation













Mutation analysis attempted, No. (%) 18 (100) 9 (90) 173 (79) 21 (91) 13 (93) 180 (81)
No. of patients with mutation(s)‡ 10 3 2 10 4 5
Specific mutations, No.
M244V 0 0 0 1 0 1
L248V 0 0 0 0 1 0
Y253H 0 0 0 0 1 0
V299L 2 2 1 0 0 0
G250E 0 0 0 0 1 2
E255K/V 0 0 0 1 1 0
D276G 0 0 0 2 0 0
T315I 6 1 1 0 0 0
F317I/L 3 0 1 0 0 2
E355G 0 0 0 1 1 0
L359C/I/V 0 0 0 4 0 0
L387M 0 0 0 1 0 0
H396P/R 0 0 0 1 0 1
E450G 0 0 0 0 1 0
No mutation, No. 8 5 24 11 8 37
No amplification,§ No. 0 1 147 0 1 138
*Includes study closure (n = 147); adverse event related to study drug (n = 42); adverse event unrelated to study drug (n = 12); withdrawal of consent and patient request
(n = 4 each); insufficient molecular response (n = 3); pregnancy (n = 2); and poor compliance/noncompliance, lost to follow-up, loss of complete cytogenetic response,
increased BCR-ABL1, and relocation to the United States (n = 1 each).
†Includes study closure (n = 162); adverse event related to study drug (n = 17); patient request (n = 10); poor compliance/noncompliance (n = 7); adverse event unrelated
to study drug and no molecular response/loss of molecular response (n = 4 each); withdrawal of consent and suboptimal response (n = 3 each); lost to follow-up,
insufficient cytogenetic response, and investigator request (n = 2 each); and pregnancy, recurrence of blasts in bonemarrow, no complete molecular response, no major
molecular response, and appearance of mutation (n = 1 each).
‡Mutations identified in dasatinib-treated patients were T315I (n = 8), V299L (n = 5), and F317I/L (n = 3). Mutations identified in imatinib-treated patients were F359C/I/V
(n = 4); G250E (n = 3); M244V, E255K/V, D276G, F317L, E355G, and H396P/R (n = 2 each); and L248V, Y253H, L387M, and E450G (n = 1 each).
§Insufficient BCR-ABL1 cDNA to assess mutations as a result of ongoing response.
Table A3. Incidence of PE in At-Risk Dasatinib-Treated Patients by the Year
They Were Reported in the Study
Year of Treatment No. of Patients at Risk No. of PE Incidents (%)
# 1 year 258 20 (8)
.1 to # 2 years 209 13 (6)
.2 to # 3 years 184 11 (6)
.3 to # 4 years 160 14 (9)
.4 to # 5 years 141 12 (9)
Abbreviation: PE, pleural effusion.
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Table A4. Any-Cause Arterial Ischemic Events
Event
No. of Patients (%)
Dasatinib 100 mg Once Daily (n = 258) Imatinib 400 mg Once Daily (n = 258)
Any Grade Grade 3 or 4 Grade 5 Any Grade Grade 3 or 4 Grade 5
Any ischemic event 12 (5) 7 (3) 2 (1) 6 (2) 3 (1) 1 (, 1)
CV event* 10 (4) 5 (2) 2 (1) 4 (2) 2 (1) 1 (, 1)
TIA 2 (1) 2 (1) 0 0 0 0
PAD 0 0 0 2 (1) 1 (, 1) 0
Abbreviations: CV, cardiovascular; PAD, peripheral arterial disease; TIA, transient ischemic attack.
*Includes myocardial infarction, angina pectoris, coronary artery disease, and acute coronary syndrome.
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